Furthermore, higher SYT11-ANGPTL2, SYT11-JAM3 and SYT11-THBS4 expression indicated poorer prognosis, especially in patients with diffuse-type GC compared to those with intestinal-type disease (Fig. 4E). This evidence concerns the gene ANGPTL2 and gastric cancer.